Araştırma Makalesi

Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy

Cilt: 12 Sayı: 2 30 Haziran 2021
PDF İndir
TR EN

Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy

Öz

Aim: Mitochondrial DNA (mtDNA) polymorphisms can be considered as a molecular marker in susceptibility to various types of cancer. In this study, we aimed to investigate the potential relationship of mtDNA polymorphisms with disease etiopathogenesis in patients with hematological malignancy. Material and Methods: This study was carried out with the participation of 80 patients diagnosed with hematological malignancy and 80 healthy individuals in the Department of Medical Genetics, Atatürk University. In all participants, 13 polymorphism regions of 6 coding genes of mtDNA were investigated by Polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. SNPs evaluated in the study; NADH dehydrogenase subunit 5-13704 (C/T), Cytochrome b 15315 (C/T), 12S rRNA 740 (G/A) and 680 (T/C), Cytochrome C Oxidase I 7319 (T/C), -7444 (G/A), Cytochrome C Oxidase II 8252 (C/G), 7660 (G/A), 7975 (A/G), 8014 (A/G), 8113 (C/A), 8152 (G/A) and tRNA lysine 8310 (T/C) were identified as. Results: ND-5 13704 (C>T) polymorphism was statistically significant in patients with hematological malignancies compared to healthy controls (p = 0.001). There was no significant difference between patients and controls in other evaluated polymorphisms. Conclusion: Although the findings obtained from this study suggest that mtDNA ND-5 13704 (C>T) polymorphism may play a role in the etiopathogenesis of hematological malignancies, large-scale studies are needed to determine the importance of this polymorphic region.

Anahtar Kelimeler

Destekleyen Kurum

Ataturk University Scientific Research Project

Proje Numarası

(2009/305)

Kaynakça

  1. 1.Lane N, Martin W. The energetics of genome complexity. Nature. 2010; 467: 929-34.
  2. 2.Wallace DC. Mitochondria and cancer. Nature Reviews Cancer. 2012; 12 :685-98.
  3. 3.Fernández‐Silva P, Enriquez JA, Montoya J. Replication and transcription of mammalian mitochondrial DNA. Experimental physiology. 2003; 88 :41-56.
  4. 4.Singh KK, Kulawiec M. Mitochondrial DNA polymorphism and risk of cancer. Cancer Epidemiology: Springer; 2009: 291-303.
  5. 5.Hertweck KL, Dasgupta S. The landscape of mtDNA modifications in cancer: a tale of two cities. Frontiers in oncology. 2017; 7: 262.
  6. 6.Hüttemann M, Lee I, Grossman LI, et al. Phosphorylation of mammalian cytochrome c and cytochrome c oxidase in the regulation of cell destiny: respiration, apoptosis, and human disease. Mitochondrial Oxidative Phosphorylation: Springer; 2012: 237-64.
  7. 7.Wang H, Xu J, Li D, Zhang S, et al. Identification of sequence polymorphisms in the mitochondrial cytochrome c oxidase genes as risk factors for hepatocellular carcinoma. Journal of clinical laboratory analysis. 2018; 32: 22299.
  8. 8.Meng X-L, Meng H, Zhang W, et al. The role of mitochondrial tRNA variants in female breast cancer. Mitochondrial DNA Part A. 2016; 27: 3199-201.

Ayrıntılar

Birincil Dil

İngilizce

Konular

Sağlık Kurumları Yönetimi

Bölüm

Araştırma Makalesi

Yayımlanma Tarihi

30 Haziran 2021

Gönderilme Tarihi

1 Nisan 2021

Kabul Tarihi

18 Mayıs 2021

Yayımlandığı Sayı

Yıl 2021 Cilt: 12 Sayı: 2

Kaynak Göster

APA
Duzkale, N., Yüce Kahraman, Ç., Kiki, İ., Yıldırım, R., Sincan, G., & Tatar, A. (2021). Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy. Turkish Journal of Clinics and Laboratory, 12(2), 147-154. https://doi.org/10.18663/tjcl.907688
AMA
1.Duzkale N, Yüce Kahraman Ç, Kiki İ, Yıldırım R, Sincan G, Tatar A. Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy. TJCL. 2021;12(2):147-154. doi:10.18663/tjcl.907688
Chicago
Duzkale, Neslihan, Çiğdem Yüce Kahraman, İlhami Kiki, Rahşan Yıldırım, Gülden Sincan, ve Abdulgani Tatar. 2021. “Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy”. Turkish Journal of Clinics and Laboratory 12 (2): 147-54. https://doi.org/10.18663/tjcl.907688.
EndNote
Duzkale N, Yüce Kahraman Ç, Kiki İ, Yıldırım R, Sincan G, Tatar A (01 Haziran 2021) Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy. Turkish Journal of Clinics and Laboratory 12 2 147–154.
IEEE
[1]N. Duzkale, Ç. Yüce Kahraman, İ. Kiki, R. Yıldırım, G. Sincan, ve A. Tatar, “Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy”, TJCL, c. 12, sy 2, ss. 147–154, Haz. 2021, doi: 10.18663/tjcl.907688.
ISNAD
Duzkale, Neslihan - Yüce Kahraman, Çiğdem - Kiki, İlhami - Yıldırım, Rahşan - Sincan, Gülden - Tatar, Abdulgani. “Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy”. Turkish Journal of Clinics and Laboratory 12/2 (01 Haziran 2021): 147-154. https://doi.org/10.18663/tjcl.907688.
JAMA
1.Duzkale N, Yüce Kahraman Ç, Kiki İ, Yıldırım R, Sincan G, Tatar A. Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy. TJCL. 2021;12:147–154.
MLA
Duzkale, Neslihan, vd. “Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy”. Turkish Journal of Clinics and Laboratory, c. 12, sy 2, Haziran 2021, ss. 147-54, doi:10.18663/tjcl.907688.
Vancouver
1.Neslihan Duzkale, Çiğdem Yüce Kahraman, İlhami Kiki, Rahşan Yıldırım, Gülden Sincan, Abdulgani Tatar. Investigation of mitochondrial DNA polymorphisms in patients with hematological malignancy. TJCL. 01 Haziran 2021;12(2):147-54. doi:10.18663/tjcl.907688

e-ISSN: 2149-8296

Publication Model: Continuous Publication

Peer Review Model: Double-Blind Peer Review

Publication Language: Turkish and English

Access Model: Open Access

DOI Prefix: (Crossref DOI numaranız)

Publisher: DNT Ortadoğu Publishing Inc.

Journal Abbreviation: Turk J Clin Lab

Indexed in J-Gate

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.